Last reviewed · How we verify

NCT04806815

Menstrual Cycle-induced Pain, Fatigue and Anxiety in Women Suffered From COVID-19

Completed Last updated 30 June 2021
What this trial tests

trial testing A survey of 60 questions was created through the internet-based 'Google Forms surveys' site. in Menstrual Problem in 180 participants. Completed in 1 June 2021.

Timeline
18 May 2021
Primary endpoint
30 May 2021
1 June 2021

Quick facts

Lead sponsorBiruni University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment180
Start date18 May 2021
Primary completion30 May 2021
Estimated completion1 June 2021
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Biruni University

Who can join

Adults 18 to 45, female only, with Menstrual Problem or Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The effects of COVID-19 on body systems and functions are still being investigated. ACE 2, which plays a key role in the entry of the COVID-19 virus into the cell, is also highly expressed in the ovary, uterus, vagina, and placenta in the female genital system, which can also pose a risk to female reproductive health. The aim of this study is to evaluate menstrual cycle-induced pain, fatigue and anxiety in women who suffered from COVID-19.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Biruni University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04806815.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing